期刊文献+

低浓度N-三甲基壳聚糖对依托泊苷经肠黏膜透过性的影响 被引量:2

Modulation effects of low-concentration N-trimethyl chitosan chloride on the permeability of etoposide across different intestinal membranes
下载PDF
导出
摘要 背景:N-三甲基壳聚糖作为透皮吸收促进剂,可以影响口服药物在体内经肠黏膜的透过性。目的:考察低浓度N-三甲基壳聚糖对依托泊苷经肠黏膜透过性的影响。方法:使用体外扩散池法评价依托泊苷经肠黏膜经时吸收方向和分泌方向的透过量和透过系数,并测定10%N-三甲基壳聚糖对依托泊苷经肠黏膜透过性的影响。依托泊苷在接受室中的浓度用高效液相色谱法测定。结果与结论:10%N-三甲基壳聚糖具有增加依托泊苷经吸收方向的透过性,减少经分泌方向的透过性。说明低浓度的N-三甲基壳聚糖可用于改善受P-糖蛋白介导药物的吸收,有望提高此类药物的口服生物利用度。 BACKGROUND: N-trimethyl chitosan as a transdermal enhancer can affect the permeability of oral drugs through the intestinal mucosa. OBJECTIVE: To investigate the modulation effects of N-trimethyl chitosan chloride on the permeability of etoposide across different intestinal membranes. METHODS: The permeability of etoposide via rat intestinal membranes was evaluated by an in vitro diffusion chamber system after the membranes were isolated from the intestine in rats with or without the co-administration of 10% N-trimethyl chitosan chloride. The concentration of etoposide in the receptor was determined by the high performance liquid chromatography. RESULTS AND CONCLUSION: With co-administration of N-trimethyl chitosan chloride at a low concentration, the absorptive directed transport of etoposide was significantly increased while its secretory directed transport was decreased. It might be possible to improve the absorption of P-glycoprotein mediated drugs by co-administration of N-trimethyl chitosan chloride at a low concentration, therefore to improve the oral bioavailability of these drugs.
出处 《中国组织工程研究》 CAS CSCD 2012年第16期2901-2904,共4页 Chinese Journal of Tissue Engineering Research
  • 相关文献

参考文献23

  • 1Bernkop-Schnürch A. Chitosan and its derivatives:potential excipients for peroral peptide delivery systems[J].International Journal of Pharmaceutics,2000,(01):1-13.
  • 2Beijnen JH,Holthuis JM,Kerkdijk HG. Degradation kinetics of etoposide in aqueous solution[J].International Journal of Pharmaceutics,1988,(1-2):169-178.
  • 3Smit EF,Carney DN,Harford P. A phase II study of oral etoposide in elderly patients with small cell lung cancer[J].Thorax,1989,(08):631-633.
  • 4Hande KR. Etoposide:four decades of development of a topoisomerase II inhibitor[J].European Journal of Cancer,1998,(10):1514-1521.
  • 5刘宏明,连传宝.肠道细胞色素P450和P-糖蛋白对口服药物生物利用度的影响[J].中国药事,2011,25(7):724-728. 被引量:6
  • 6Pleban K,Kopp S,Csaszar E. P-glycoprotein substrate binding domains are located at the transmembrane domain/ transmembrane domain interfaces:a combined photoaffinity labeling-protein homology modeling approach[J].Molecular Pharmacology,2005,(02):365-374.
  • 7Rosenberg MF,Callaghan R,Modok S. Three-dimensional structure of P-glycoprotein:the transmembrane regions adopt an asymmetric configuration in the nucleotide-bound state[J].Journal of Biological Chemistry,2005,(04):2857-2862.
  • 8缪泽鸿,丁健.抗肿瘤多药耐药的研究进展[J].癌症,2003,22(8):886-892. 被引量:14
  • 9贺云霞,孙进,程刚.多药耐药性P-糖蛋白在药物肠道吸收中的作用[J].沈阳药科大学学报,2004,21(5):389-393. 被引量:23
  • 10何娟,刘晓磊,彭文兴.P-糖蛋白介导的肿瘤多药耐药逆转机制研究进展[J].中国药房,2006,17(3):218-220. 被引量:14

二级参考文献177

共引文献96

同被引文献24

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部